Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ATON vs MREO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MREO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–1 Matrix Metrics)

MREO Overall Winner 6-Pillar Tally: ATON 0 – 4 MREO (2 Tie) Matrix Metrics: ATON 1 – 6 MREO

As of Nov 16, 2026, Mereo BioPharma Group plc (MREO) is the stronger overall head-to-head candidate over AlphaTON Capital Corp. (ATON) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ATON carries a Unified Composite Score of 45.1/100 (HOLD) at $0.32 (N/M Forward P/E, 0.0% operating margin), whereas MREO carries 46.9/100 (HOLD) at $0.30 (113.9x Forward P/E, -3702.5% operating margin).

  • Technical & Structure Timing Caution: ATON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.3); meanwhile MREO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATON vs MREO
ATON NASDAQ
AlphaTON Capital Corp. Common Stock
Finance Services
$0.32
+0.0% 1D
Market Cap $7.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 65% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.2%), weak momentum, RSI 41
RSI-14: 41.3 · SMA20: $0.32 · SMA50: $0.38
MREO NASDAQ Head-to-Head Winner
Mereo BioPharma Group plc American Depositary Shares
Pharmaceutical Preparations
$0.30
-1.33% 1D
Market Cap $48.7M
TTM Revenue $800,000
Forward P/E 113.9x
Beta / 30D Vol 1.09β · 48% Vol
Unified Composite Score
46.9 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.3 · SMA20: $0.29 · SMA50: $0.31

6-Pillar Scorecard Institutional Category Breakdown (ATON 0 – 4 MREO)

Columns: Metric · ATON · MREO
1. Valuation Multiples MREO
Forward P/E N/M 113.9x
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 60.9x
2. Growth & Scale MREO
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $800,000
Market Cap $7.5M $48.7M
3. Profitability & Quality MREO
Gross Margin N/A 100.0%
Operating Margin 0.0% -3702.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -311.0% -76.6%
4. Balance Sheet & Cash Flow MREO
Cash Generation (TTM) N/A -$29M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.67 Book/Sh · -311.0% ROE $0.15 Book/Sh · -76.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.5% (<1st %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Asset Management Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATON (1) vs MREO (6)
Institutional Metric ATON MREO Criterion Row Edge
Market Capitalization
Scale
$7.5M $48.7M Larger Scale MREO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 113.9x Lower Multiple MREO
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -3702.5% Higher Margin ATON
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-311.0% -76.6% Higher ROE MREO
52-Week Range Position
Momentum
0% ($0–$14) 5% ($0–$2) Stronger Trend MREO
Beta / 30D Volatility
Risk Regime
1.90β · 65% Vol 1.09β · 48% Vol Lower Realized Risk MREO
Unified Institutional Score
Composite Signal
45.1 / 100 (HOLD) 46.9 / 100 (HOLD) Higher Composite MREO
Trailing 12M Revenue (USD)
Operating Scale
N/A $800,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 60.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.67 Book/Sh · -311.0% ROE) -$29M EBITDA ($0.15 Book/Sh · -76.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MREO +0.14 pp
ATON: -6.71% · MREO: -6.57%
3M Horizon MREO +10.01 pp
ATON: -57.35% · MREO: -47.34%
6M Horizon MREO +9.84 pp
ATON: -90.91% · MREO: -81.07%
1Y Horizon MREO +9.84 pp
ATON: -90.91% · MREO: -81.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATON vs MREO. Trailing 12-month operating profitability (ATON 0.0% vs MREO -3702.5%) and valuation multiples (ATON N/M vs MREO 113.9x Forward P/E) are benchmarked directly in Pillar 4 below.

ATON ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-311.0% · N/M
MREO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$800,000
Gross Margin100.0%
Op. Margin-3702.5%
ROE / Fwd P/E-76.6% · 113.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATON UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MREO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MREO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATON Moat Profile Cyclical / Execution-Driven Positioning
Asset Management Operator
Competes within the Asset Management value chain with $7.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MREO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $48.7M market capitalization and -3702.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATON vs MREO Key Questions & Quantitative Answers

As of Nov 16, 2026, Mereo BioPharma Group plc (MREO) is the stronger overall head-to-head candidate over AlphaTON Capital Corp. (ATON) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ATON carries a Unified Composite Score of 45.1/100 (HOLD) at $0.32 (N/M Forward P/E, 0.0% operating margin), whereas MREO carries 46.9/100 (HOLD) at $0.30 (113.9x Forward P/E, -3702.5% operating margin). Technical & Structure Timing Caution: ATON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.3); meanwhile MREO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MREO leads the Growth & Scale pillar: ATON posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MREO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $800,000 TTM revenue (100.0% gross margin, -3702.5% operating margin). On trailing 12-month operating scale, ATON generates N/A in USD-normalized revenue versus $800,000 for MREO. In operating R&D and SG&A reinvestment, ATON deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MREO.

MREO screens cheaper on headline valuation multiples. ATON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MREO trades at 113.9x Forward P/E, N/M Trailing P/E, N/M PEG, and 60.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATON (-311.0% ROE) versus MREO (-76.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ATON carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.90β · 65% Vol realized risk). By comparison, MREO carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.